Clinical Trial Update: A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients [Phase 4]

View source ↗

Summary

Phase 4 trial updates two doses of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia in transplant-eligible patients; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Inotuzumab ozogamicin (inotuzumab ozogamicin)

Snippet

Sponsor: Pfizer | Conditions: Leukemia, Precursor b-Cell Lymphoblastic Leukemia-Lymphoma | Phase 4 | Status: COMPLETED | Results posted: 2023-11-22